Business
Soleno Therapeutics Announces Select Preliminary Fourth Quarter and Full-Year 2025 Results
REDWOOD CITY, Calif., Jan. 12, 2026 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (Soleno) (NASDAQ: SLNO), a biopharmaceutical company developing novel
About this update from Soleno Therapeutics, Inc.
[{"type":"text","content":"REDWOOD CITY, Calif., Jan. 12, 2026 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (Soleno) (NASDAQ: SLNO), a biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today announced select preliminary financial and operating results for the fourth quarter and full-year 2025: Preliminary unaudited full-year 2025 net revenue related to U.S. sales of VYKAT™ XR since second quarter launch expected to be in a range of $189 million to $191 million.Preliminary unaudited fourth quarter 2025 net revenue expected to be in a range of $90 million to $92 million.1,250 total new patient start forms (207 in the fourth quarter) from launch through December 31, 2025, or approximately 12.5% of the total U.S. VYKAT XR addressable market.Discontinuation rate of VYKAT XR related to adverse events was approximately 12% as of the end of the fourth quarter.630 unique prescribers, including 136 new prescribers in the fourth quarter.Over 185 million lives covered, or approximately 60% of total lives.Company has responded to Day 120 questions received from the European Medicines Agency.Company has achieved profitability and positive cash flow.Year-end 2025 cash, cash equivalents and marketable securities were approximately $500 million, after the $100 million accelerated share repurchase program that the Company announced on November 11, 2025. “Our strong fourth quarter results cap a truly transformational year for Soleno Therapeutics, driven by the approval and successful launch of VYKAT XR in the U.S.,” said Dr. Anish Bhatnagar, Chief Executive Officer and Chairman of the Board of Soleno Therapeutics. “In less than nine months since launch, we have received patient start forms representing well over 10% of our addressable U.S. Prader-Willi syndrome (PWS) patient population. This reflects the significant unmet medical need that VYKAT XR can address as well as our success in communicating VYKAT XR’s value proposition to payers, providers and caregivers.” “Looking ahead, as we continue to raise awareness of this first-to-market hyperphagia treatment, we have the opportunity to significantly impact the lives of many more patients and families living with PWS while simultaneously creating sustained value for our company. We are well-funded, our leading indicators are strong, and I am excited for what the future holds in 202...